The "Psoriatic Arthritis: Epidemiology Forecast to 2033" report has been added to ResearchAndMarkets.com's offering. This report provides an overview of the risk factors, comorbidities, and global and ...

Researchers identified 3 distinct PsA phenotype clusters, emphasizing the importance of PsO severity in treatment decision making.

For patients with psoriatic arthritis, switching directly from adalimumab to tofacitinib with no washout period presents no ...

In 2024, the FDA approved 19 biosimilars across various therapeutic areas, including the first biosimilars for ustekinumab ...

Bimekizumab (Bimzelx; UCB Pharma) was approved by the FDA to treat psoriatic arthritis (PsA) on September 23, 2024, based on ...

Topline data were announced from two phase 3 trials evaluating deucravacitinib in adults with active psoriatic arthritis.

Misuse of screening tools and subsequent underdiagnosis of the condition can easily occur, even amongst specialists.

UCB SA (OTCMKTS:UCBJY – Get Free Report)’s stock price passed below its 50-day moving average during trading on Monday . The stock has a 50-day moving average of $96.49 and traded as low as $93.22.

Can a protein involved in delivering Vitamin D to target tissues have an altered serum profile in psoriasis patients with ...

Stull said that a number of prescription treatments exist for topical psoriasis, such as steroids and injectable therapies, ...